Successful Treatment with Dapsone for Refractory Immune Thrombocytopenia

Yasuhiro Maeda *

Department of Hematology, National Hospital Organization, Osaka Minami Medical Center, Japan.

Kenta Yamamoto

Department of Hematology, National Hospital Organization, Osaka Minami Medical Center, Japan.

Ayano Fukui

Department of Hematology, National Hospital Organization, Osaka Minami Medical Center, Japan.

Go Eguchi

Department of Hematology, National Hospital Organization, Osaka Minami Medical Center, Japan.

Terufumi Yamaguchi

Department of Hematology, National Hospital Organization, Osaka Minami Medical Center, Japan.

*Author to whom correspondence should be addressed.


Abstract

In adult with immune thrombocytopenia (ITP), it has been known that steroids have been used as a first-line therapy. The therapy induced remission in more than 60% of patients. Here, we evaluated the results of dapsone for a steroid-resistant ITP patient. Further, dapsone has been reported to emerge as a safe and inexpensive therapy for chronic ITP. In this case, we showed a relationship between platelet count and grade of hemolysis by treatment with dapsone.

Keywords: ITP, drug-resistance, dapsone, hemolysis


How to Cite

Maeda, Yasuhiro, Kenta Yamamoto, Ayano Fukui, Go Eguchi, and Terufumi Yamaguchi. 2014. “Successful Treatment With Dapsone for Refractory Immune Thrombocytopenia”. International Journal of Medical and Pharmaceutical Case Reports 2 (3):57-60. https://doi.org/10.9734/IJMPCR/2015/13139.

Downloads

Download data is not yet available.